News coverage about BioDelivery Sciences International (NASDAQ:BDSI) has been trending somewhat positive on Tuesday, Accern reports. The research group identifies positive and negative media coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. BioDelivery Sciences International earned a media sentiment score of 0.17 on Accern’s scale. Accern also assigned news stories about the specialty pharmaceutical company an impact score of 46.7520016664199 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.

Here are some of the news stories that may have impacted Accern Sentiment’s rankings:

BioDelivery Sciences International (NASDAQ BDSI) opened at 2.75 on Tuesday. BioDelivery Sciences International has a 12-month low of $1.50 and a 12-month high of $3.60. The company has a market cap of $152.56 million, a price-to-earnings ratio of 98.21 and a beta of 1.04. The stock has a 50 day moving average price of $3.10 and a 200-day moving average price of $2.47.

BioDelivery Sciences International (NASDAQ:BDSI) last released its quarterly earnings data on Wednesday, August 9th. The specialty pharmaceutical company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by ($0.04). The business had revenue of $8.70 million during the quarter, compared to the consensus estimate of $8.45 million. BioDelivery Sciences International had a net margin of 3.34% and a return on equity of 14.64%. The business’s revenue was up 74.0% compared to the same quarter last year. During the same period last year, the company posted ($0.31) earnings per share. On average, analysts predict that BioDelivery Sciences International will post $0.12 EPS for the current fiscal year.

Several research analysts have issued reports on BDSI shares. HC Wainwright set a $4.00 price target on BioDelivery Sciences International and gave the stock a “buy” rating in a report on Saturday, June 10th. Cantor Fitzgerald restated an “overweight” rating on shares of BioDelivery Sciences International in a report on Sunday, August 20th. Zacks Investment Research lowered BioDelivery Sciences International from a “buy” rating to a “hold” rating in a report on Monday, July 17th. ValuEngine lowered BioDelivery Sciences International from a “hold” rating to a “sell” rating in a report on Friday, June 2nd. Finally, Janney Montgomery Scott raised their target price on BioDelivery Sciences International from $3.00 to $4.00 and gave the company a “fair value” rating in a report on Monday, July 24th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and five have issued a buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $4.21.

COPYRIGHT VIOLATION NOTICE: This article was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this article on another site, it was illegally stolen and reposted in violation of U.S. and international copyright legislation. The original version of this article can be viewed at

BioDelivery Sciences International Company Profile

BioDelivery Sciences International, Inc is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction.

Insider Buying and Selling by Quarter for BioDelivery Sciences International (NASDAQ:BDSI)

Receive News & Stock Ratings for BioDelivery Sciences International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International Inc. and related stocks with our FREE daily email newsletter.